A Randomized, Multicenter, Long Term Study of the Safety of Tanezumab in Patients With Chronic Low Back Pain.

Trial Profile

A Randomized, Multicenter, Long Term Study of the Safety of Tanezumab in Patients With Chronic Low Back Pain.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Tanezumab; Tanezumab
  • Indications Back pain
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 11 May 2013 Results from an extension trial presented at the 32nd Annual Scientific Meeting of the American Pain Society.
    • 23 Dec 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 19 Jul 2010 Status changed from recruiting to suspended, based on a Pfizer media release. Adverse events were noted tanezumab recipients with osteoarthritis, and the FDA requested suspension based on the potential for adverse events in other patient populations.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top